| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C22orf1 |
| Uniprot No | O15442 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-326aa |
| 氨基酸序列 | MWRSRWDASVLKAEALALLPCGLGMAFSQSHVMAARRHQHSRLIIEVDEYSSNPTQAFTFYNINQGRFQPPHVQMVDPVPHDAPKPPGYTRFVCVSDTHSRTDPIQMPYGDVLIHAGDFTELGLPSEVKKFNEWLGSLPYEYKIVIAGNHELTFDQEFMADLIKQDFYYFPSVSKLKPENYENVQSLLTNCIYLQDSEVTVRGFRIYGSPWQPWFYGWGFNLPRGQALLEKWNLIPEGVDILITHGPPLGFLDWVPKKMQRVGCVELLNTVQRRVQPRLHVFGHIHEGYGVMADGTTTYVNASVCTVNYQPVNPPIVIDLPTPRNS |
| 分子量 | 61.6 KDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人C22orf1蛋白的3篇代表性文献的摘要概括（内容基于虚构假设，仅供参考）：
1. **文献名称**：*"重组人C22orf1蛋白在大肠杆菌中的高效表达及其纯化"*
**作者**：Zhang et al.
**摘要**：研究通过大肠杆菌表达系统成功表达重组人C22orf1蛋白，并优化纯化条件获得高纯度产物。实验表明该蛋白具有可溶性表达特性，为后续功能研究奠定基础。
2. **文献名称**：*"C22orf1通过调控Wnt/β-catenin通路抑制结直肠癌细胞增殖"*
**作者**：Li & Wang
**摘要**：研究发现重组C22orf1蛋白可通过抑制Wnt/β-catenin信号通路，降低结直肠癌细胞活力，提示其可能作为肿瘤治疗的潜在靶点。
3. **文献名称**：*"重组C22orf1蛋白的核定位信号及其细胞功能分析"*
**作者**：Chen et al.
**摘要**：通过基因编辑和荧光标记技术，揭示C22orf1蛋白含有功能性核定位信号，并发现其与DNA损伤修复相关蛋白存在相互作用，可能参与基因组稳定性调控。
注：若需真实文献，建议通过PubMed或Google Scholar以“C22orf1 recombinant protein”为关键词检索。
C22orf15, also termed chromosome 22 open reading frame 15 (sometimes ambiguously referenced as C22orf1), is a protein-coding gene located on human chromosome 22q13.2. The encoded protein, though not extensively characterized, is predicted to contain approximately 230 amino acids with a molecular weight of ~25 kDa. It is evolutionarily conserved across eukaryotes, suggesting a fundamental cellular role. Current evidence indicates potential involvement in mitochondrial function, with some studies linking it to interactions with mitochondrial complex I subunits. Additionally, bioinformatic analyses propose roles in cell cycle regulation or stress response pathways, though mechanistic details remain unclear. Its recombinant form (recombinant human C22orf15) is engineered for in vitro studies, often expressed in prokaryotic or mammalian systems for functional assays. Aberrant expression of C22orf15 has been tentatively associated with neurodevelopmental disorders and cancers, possibly through dysregulation of energy metabolism. However, its precise biological functions, physiological substrates, and pathological relevance require further validation. Research efforts continue to explore its molecular interactions and potential as a therapeutic target or biomarker, hampered by limited antibody availability and incomplete structural data.
×
